Orbital decompression surgery among Medicare beneficiaries in the post-teprotumumab era.
Akash M BhatZachary M SolerRodney J SchlosserRalph B MetsonVinay K RathiPublished in: International forum of allergy & rhinology (2024)
Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019. FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: -14.9%) from 2019 to 2022. In 2022, total spending was substantially higher for teprotumumab ($325 million) than surgery ($580,000).